| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8794675 | Ophthalmology Retina | 2018 | 11 Pages |
Abstract
The decrease in sVEGF is greater with bevacizumab than with ranibizumab, but this difference is eliminated when treatment is withheld for 3 months. Higher sVEGF increased the hazard of an ATE and bevacizumab increases the hazard of an IME compared with ranibizumab.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Chris A. BSc, PhD, Lauren J. MSc, Barnaby C. DPhil, MSc, Susan FRCOphth, MD, Andrew J. FRCOphth, MD, Andrew D. FRCS, MD, Usha MD, PhD, IVAN trial investigators IVAN trial investigators,